Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder : a 4-week placebo-controlled trial

A double-blind, placebo-controlled, multicenter study, was performed to evaluate the efficacy and safety of ziprasidone in 139 patients with an acute exacerbation of schizophrenia or schizoaffective disorder. Patients were randomized to receive ziprasidone 40 mg/day, 120 mg/day or placebo for 28 day...

Ausführliche Beschreibung